레버 선천성 흑암시(LCA) : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서, 2026-2036년

Leber Congenital Amaurosis Market Outlook and Forecast

Thelansis's "Leber Congenital Amaurosis (LCA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Leber Congenital Amaurosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Leber Congenital Amaurosis Overview

Leber congenital amaurosis (LCA) is a group of inherited retinal dystrophies caused by variants in genes essential for photoreceptor function and the visual cycle. It usually presents in infancy with severe visual impairment, nystagmus, and poor visual responses; phenotype and progression vary by genotype. Management includes visual rehabilitation, low-vision support, educational services, and genetic counseling. Voretigene neparvovec (Luxturna) is FDA-approved for biallelic RPE65 mutation-associated retinal dystrophy, establishing gene augmentation in a defined subgroup. The development landscape includes gene-specific and genome-editing approaches. ATSN-101 is being studied for GUCY2D-associated LCA, while EDIT-101 uses CRISPR-Cas9 editing for a specific CEP290 variant causing LCA10. RNA-based strategies remain investigational globally. Key challenges include genetic heterogeneity, retinal degeneration, ocular delivery, durability, and treatment before substantial photoreceptor loss.

Key Highlights

• In the United States, LCA prevalence cases are projected to increase from 59,596 in 2026 to 65,506 by 2036.
• LCA is a rare inherited retinal disorder causing severe visual impairment from early childhood.
• Progressive vision loss and limited treatment options create a significant disease burden.
• Significant unmet need remains for therapies that preserve or restore vision.

Market Overview

• The Germany LCA market is projected to grow from $130M in 2026 to $200M by 2036.
• Market growth is driven by:
• Increasing adoption of gene therapy and emerging retinal therapies
• Advances in genetic diagnosis and disease understanding
• Future growth will depend on durable treatments that preserve or improve visual function.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026-2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Opus Genetics, Inc.
• Spark Therapeutics, Inc.
• Ocugen
• Atsena Therapeutics Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)